Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 18/20 | 0.60 |
| ▸ | CLK2 | P49760 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492566 | 0.89 | BTK (0.60) | BTKCLK2KDM4ERAB9ATYK2 | |
| SCHEMBL107656 | 0.88 | BTK (0.69) | BTKCLK2 | |
| SCHEMBL108055 | 0.88 | BTK (0.58) | BTKCLK2KDM4ERAB9ATYK2 | |
| SCHEMBL104439 | 0.87 | BTK (0.77) | BTKCLK2 | |
| SCHEMBL3804473 | 0.84 | BTK (0.63) | BTKCLK2KDM4ERAB9ATYK2 | |
| SCHEMBL103784 | 0.83 | BTK (0.67) | BTKCLK2 | |
| SCHEMBL3660016 | 0.82 | BTK (0.62) | BTKCLK2KDM4ERAB9ATYK2 | |
| SCHEMBL105793 | 0.82 | BTK (0.59) | BTKCLK2 | |
| SCHEMBL105988 | 0.81 | BTK (0.64) | BTKCLK2 | |
| SCHEMBL3659635 | 0.81 | BTK (0.61) | BTKCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426109-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-7943618-B2 | Btk protein kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943618-B2 | Btk protein kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943618-B2 | Btk protein kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | BTK 1/4885CLK2 552/4885KDM4E 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.